She researches and writes primarily in the areas of drug and device regulation, intellectual property, and administrative law. Some of her more recent scholarship has focused on the possibility of reverse payment patent settlements between biologic innovators and biosimilar sponsors, data exclusivity for drugs and biologics, mandatory release of clinical data in drug applications, generic drug exclusivity, preemption of failure to warn suits against generic and innovative drug companies, and conflicts of interest on FDA advisory committees. Also, she has recently written book chapters on the regulation of biosimilar biological products and the regulation of drug and device clinical trials. She has also written more than a dozen shorter pieces for a variety of other publications, including two empirical pieces on judicial review of FDA action.